Nearly two months after winning CE Mark approval in European Union for its Cerene device, Channel Medsystems brought in a Series C1 round worth $14.1 million.
Participants included previous backers Boston Scientific (NYSE:BSX), Third Point Ventures, InCube Ventures, Aperture Venture Partners, Scientific Health Development and Longwood Fund, the Emeryville, Calif.-based company said.
Cerene, a cryogen-based endometrial ablation system designed to treat heavy menstrual bleeding, won the CE Mark nod in June. In the U.S., the treatment phase is complete in a 242-woman pivotal investigational device exemption trial.
“I am proud of the achievements the team at Channel has made this year,” president & CEO Ric Cote said in prepared remarks. “We remain focused on delivering an exceptional device and treatment experience to women and their physicians, and we appreciate the continued support of our investors in this process.”
On June 4-5, DeviceTalks is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring, bringing you the best and brightest minds in the industry.
Heidi Dohse: Sr. Program Manager, Healthcare, Google, Founder, Tour de Heart Foundation, Acessa Health Inc. Michael J. Pederson: Senior Vice President, Cardiac Arrhythmias and Heart Failure Division, Abbott Hon. Melvin Carter: Mayor, Saint Paul Tim Philips: Compliance Officer, FDA’s Office of Medical Device and Radiological Health Operations Dr. Myriam J. Curet, MD, FACS: Chief Medical Officer, Intuitive Surgical
Take a look at our incredible line up of speakers and join us now.
Use the code "KEYNOTE" to save 15% on the cost of registration.